Cenegermin in Pediatric Neurotrophic Keratopathy

Pedrotti, Emilio; Bonetto, Jacopo; Cozzini, Tiziano; Fasolo, Adriano; Marchini, Giorgio

doi:10.1097/ico.0000000000002112

Cited by 20 publications

(21 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 1 , 4 ] Among uncommon causes that can lead to NK, congenital diseases such as familial dysautonomia (Riley-Day syndrome), Goldenhar-Gorlin syndrome, Mobius syndrome, and familial trigeminal anesthesia have also been described. [ 2 , 5 ]…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops

et al. 2020

View full text Add to dashboard Cite

Rationale: To report the management of recalcitrant neurotrophic keratopathy in a pediatric patient affected by pontine tegmental cap dysplasia (PTCD) using topical human recombinant nerve growth factor (hrNGF, Cenegermin 20 μg/ml). To the best of our knowledge the present case is one of the few described in patients with congenital NK treated with Cenegermin, and the first in a patient affected by PTCD. Patient Concerns: A 9-year-old patient, affected by PTCD with bilateral cranial nerve V 1 and VIII palsies, was referred to our hospital for visual disturbances and redness of the right eye due to persistent neurotrophic epithelial defect. The patient presented marked developmental delay, ataxia, bilateral hypoacusia, and bilateral corneal severe hypoaesthesia. Ocular history revealed multiple treatments in order to treat neurotrophic ulcer in the left eye. Four years later, he developed a persistent epithelial defect with corneal anesthesia in the right eye. Diagnoses: The impaired trigeminal nerve function, due to the underlying congenital disease, led to the development of moderate NK (stage II) in the right eye and a mild NK (stage I) in the left eye. Interventions: Cenegermin 20 μg/ml eye-drop was administered in both eyes. Treatment was continued for 8 weeks. The patient was assessed after 4 and 8 week of treatment. At each follow-up visit, treatment efficacy and adverse events were evaluated. Outcomes: The use of Cenegermin eye drops facilitated the remarkable resolution of the neurotrophic keratopathy and the improvement of corneal sensitivity in both eyes. No local or systemic adverse events were observed. Lessons: Topical Cenegermin 20 μg/ml was well-tolerated and may represent a valuable therapeutic option in the management of pediatric neurotrophic keratopathy.

show abstract

Section: Introductionmentioning

confidence: 99%

“…To the best of our knowledge, only few cases of patients with congenital NK treated with Cenegermin have been reported. [ 2 , 5 ]…”

Section: Introductionmentioning

confidence: 99%

A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops

et al. 2020

View full text Add to dashboard Cite

show abstract

“…On one hand, various case reports showed the successful outcomes of this treatment in pediatric NK owing to different etiologies. 10 , 13 , 14 , 15 , 16 , 17 On the other hand, a recent case series (9 eyes of 8 pediatric patients) provided modest support for the efficacy of NGF in this setting, reporting an improvement of corneal ulcer stage in 5 eyes and best-corrected visual acuity in 2 eyes. 7 However, in our case it was not possible to use this drug and obtain its reimbursement due to local regulatory issues.…”

Section: Discussionmentioning

confidence: 99%

Maternal serum eye drops to treat bilateral neurotrophic keratopathy in congenital corneal anesthesia: Case report and literature review

Giannaccare

Lucisano

Pellegrini

et al. 2022

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

“…Additional studies have shown that cenegermin is safe and effective for use in pediatric patients ≥ 2 years old and is now permitted for use in children in the USA [49]. The most common side effects of cenegermin include eye and eyelid pain, inflammation, increased tearing, and foreign body sensation in the eye [50]. No current concensus on timing of cenegermin for the treatment of NK is established; however, it is generally reserved for treatment of moderate to severe NK to aid corneal healing and prevent progression to corneal melt.…”

Section: Cenegermin (Oxervate™)mentioning

confidence: 99%

“…Nicergoline is a derivative of ergoline that is typically used to treat cognitive impairment due to degenerative dementia or stroke [50,51]. Administered orally, the drug is thought to increase the healing of corneal epithelial wounds by increasing levels of NGF in the cornea and lacrimal glands, as evidenced by rat studies [42,52].…”

Section: Nicergoline (Sermion®)mentioning

confidence: 99%

Corneal Neurotization and Novel Medical Therapies for Neurotrophic Keratopathy

Rosenblatt

Sears

Park

et al. 2020

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Purpose of Review Neurotrophic keratopathy (NK) is a degenerative corneal disease characterized by decreased corneal sensibility and impaired corneal healing. In this article, we review surgical techniques for corneal neurotization (CN) and novel medical therapies for the treatment of NK. Recent Findings In recent decades, there has been a paradigm shift in the treatment strategies for NK. New minimally invasive direct and indirect CN approaches have demonstrated efficacy at improving best-corrected visual acuity and central corneal sensation while decreasing surgical morbidity. In addition, several targeted medical therapies, such as recombinant human nerve growth factor (rhNGF), regenerating agents (RGTA), and nicergoline, have shown promise in improving corneal epithelial healing. Of these options, cenegermin (Oxervate®, Dompé), a topical biologic medication, has emerged as an approved medical treatment for moderate to severe NK. Summary NK is a challenging condition caused by alterations in corneal nerves, leading to impairment in sensory and trophic function with subsequent breakdown of the cornea. Conventional therapy for NK depends on the severity of disease and focuses primarily on protecting the ocular surface. In recent years, numerous CN techniques and novel medical treatments have been developed that aim to restore proper corneal innervation and promote ocular surface healing. Further studies are needed to better understand the long-term efficacy of these treatment options, their target populations, and the potential synergistic efficacy of combined medical and surgical treatments.

show abstract

Cenegermin in Pediatric Neurotrophic Keratopathy

Cited by 20 publications

References 4 publications

A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops

A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops

Maternal serum eye drops to treat bilateral neurotrophic keratopathy in congenital corneal anesthesia: Case report and literature review

Corneal Neurotization and Novel Medical Therapies for Neurotrophic Keratopathy

Contact Info

Product

Resources

About